GET DAILY SIGNALSWhy Is ImmunityBio (IBRX) Stock Down -5.66% Today?
Key Takeaways
- Shares fell roughly 5.7% to around $8.66, extending a multi-session slide from Friday's close of $9.18.
- The decline reflects a "sell the news" reaction after the FDA's Oct. 14 expansion of the Anktiva label in bladder cancer.
- Long-term QUILT-3.032 data published last week confirmed known efficacy but offered no fresh upside catalyst.
- Valuation and balance-sheet concerns — a near-$10 billion market cap on modest revenue, heavy debt, and ongoing cash burn — are weighing on sentiment.
- Technical momentum turned bearish, with a MACD crossover and weakening short-term indicators.
- Traders are watching the company's next earnings report and updates on the BCG-naïve QUILT-2.005 trial.
Opening Summary
ImmunityBio, Inc. (IBRX), a San Diego–based clinical-stage immunotherapy company best known for its IL-15 superagonist Anktiva, is trading sharply lower on Monday. Shares of IBRX were down about 5.66% to roughly $8.66 in intraday trading, after closing the prior completed session at $9.18. The move marks a continuation of a week-long retreat that has erased much of the stock's post-approval pop, as investors digest an FDA decision that was widely anticipated and lock in gains from a massive year-to-date run.
"Sell the News" After the FDA Approval
The dominant driver behind IBRX's slide is a classic "sell the news" dynamic. On Oct. 14, the U.S. Food and Drug Administration expanded the approved indication for Anktiva in combination with Bacillus Calmette-Guérin (BCG) to include adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with high-grade papillary-only disease — making it the first therapy cleared for that specific population. While the label expansion meaningfully widens the addressable patient pool, the outcome had been heavily telegraphed: the National Comprehensive Cancer Network had already added the regimen to its guidelines months earlier, and the decision arrived nearly three months ahead of the FDA's January 2027 target date.
As a result, the approval generated only a brief intraday pop before fading. The subsequent publication of long-term data from the pivotal QUILT-3.032 trial — showing durable complete responses, a median response duration of 26.6 months, and 84% cystectomy-free survival at three years — confirmed efficacy that was already reflected in the share price rather than introducing new information. With no fresh positive catalyst, momentum reversed.
Valuation and Balance-Sheet Pressures
Beneath the headline news, investors are contending with a stretched valuation. Even after the recent pullback, IBRX trades at roughly 55–60 times trailing revenue on a market capitalization near $10 billion, while trailing twelve-month revenue sits in the mid-$160 million range. The company remains deeply unprofitable, with negative operating margins, more than $1.7 billion in debt against a comparatively thin cash position, and an annual free-cash-flow burn in the hundreds of millions of dollars.
That financial profile leaves little room for disappointment and makes the stock sensitive to any shift in risk appetite. Ongoing insider selling — including recent director transactions executed under pre-arranged 10b5-1 trading plans — has added to the cautious tone among retail traders, even as sell-side analysts have largely maintained Buy-equivalent ratings and lifted price targets.
Technical Weakness and Profit-Taking
The decline is also being amplified by technical factors. After rallying more than 360% year-to-date from a 52-week low of $1.95 to a high of $12.43, IBRX had become extended, and the recent retreat has triggered bearish short-term signals. Short-term momentum indicators have deteriorated, with a MACD crossover into negative territory and a sharp drop in stochastic readings, indicating that near-term buying momentum has cooled. The shares have given back a meaningful portion of October's gains as speculative positioning unwinds.
Market Context and Trading Activity
Trading volume has remained elevated relative to the stock's longer-term average, reflecting active two-way flow as investors reassess the post-approval setup. The move has generally tracked weakness across the broader small- and mid-cap biotechnology complex rather than a company-specific shock, with sentiment toward speculative, pre-profit biotech names turning more cautious. While large-cap indices have been comparatively resilient, high-beta, momentum-driven names like IBRX have underperformed as traders rotate away from extended positions.
What Comes Next for IBRX
Looking ahead, investors will focus on the company's next quarterly earnings report, currently anticipated in early November, for signs that the expanded Anktiva label is translating into prescription growth and improved reimbursement traction. Additional attention centers on the QUILT-2.005 trial in BCG-naïve NMIBC — a substantially larger patient population — along with earlier-stage programs in lung cancer, glioblastoma, and pancreatic cancer that would be needed to justify the current valuation. Key risks include slower-than-expected commercial uptake, ongoing cash-burn pressures that may necessitate additional financing, and the possibility that future pipeline readouts disappoint against elevated expectations.
Trending AI Robots
For traders seeking a data-driven edge in volatile markets, Tickeron's Trending AI Robots page offers a curated look at its strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating superior performance under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to find approaches aligned with their own objectives. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for IBRX shows an upward move is likely
IBRX's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator showed a similar pattern. In 115 of the 123 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
IBRX moved above its 50-day moving average on September 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 49 cases where IBRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 44 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
IBRX broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.296) is normal, around the industry mean (2.835). P/E Ratio (-9.663) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement